Home / Business News (page 5)

Business News

Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases

RARITAN, N.J., Jan. 31, 2019  — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc (NASDAQ: MGTX), a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leading product candidates for achromatopsia (ACHM) caused …

Read More »

Centogene Develops New Validation Framework to Optimize Specificity and Sensitivity in Whole Exome Sequencing-Based Diagnostics

ROSTOCK, Germany–(BUSINESS WIRE)–CENTOGENE, a rare disease company committed to improving the lives of rare disease patients by providing solutions that accelerate the development of drugs, has published the development of a rationale framework to optimize sensitivity and specificity in whole exome sequencing (WES)-based diagnostics of a clinically heterogeneous patient population …

Read More »

Genentech to Discontinue Phase 3 CREAD 1 and 2 Studies of Crenezumab in Early Alzheimer’s Disease

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with early (prodromal to mild) sporadic Alzheimer’s disease (AD). …

Read More »

Aldeyra Therapeutics Expands Retinal Disease Pipeline With Acquisition Of Helio Vision

LEXINGTON, Mass., Jan. 29, 2019 /PRNewswire/ — Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it has acquired Helio Vision, Inc. (Helio Vision), a privately held biotechnology company. The acquisition adds to Aldeyra’s pipeline a Phase 3-ready …

Read More »

Neurocrine Biosciences and Voyager Therapeutics Form Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

SAN DIEGO and CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR), today announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, …

Read More »

Celgene Partners with FACIT and Triphase Accelerator for Preclinical Blood Cancer Drug

TORONTO, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) — Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia. Triphase is a drug development company advancing novel compounds …

Read More »

Thermo Fisher Scientific Agrees to Sell its Anatomical Pathology Business to PHC Holdings for $1.14 Billion

WALTHAM, Mass., Jan. 28, 2019 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has signed a definitive agreement to sell its Anatomical Pathology business to PHC Holdings Corporation, a global innovator in healthcare solutions, for approximately $1.14 billion in cash. …

Read More »

Horizon Discovery and Rutgers University Form Exclusive Partnership to Develop Next Generation Novel Gene Editing Technology

CAMBRIDGE, England–(BUSINESS WIRE)–Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Group”), a global leader in gene editing and gene modulation technologies, today announces that it has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey (US), to develop and commercialise a novel gene editing …

Read More »

Coherus Reaches Settlement with AbbVie, Securing Rights to Commercialize its Adalimumab Biosimilar Candidate, CHS-1420

REDWOOD CITY, Calif., Jan. 25, 2019 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has executed settlement agreements with AbbVie Inc. that grant Coherus global, non-exclusive license rights under AbbVie’s intellectual property to commercialize CHS-1420, Coherus’ proposed adalimumab (HUMIRA®) biosimilar.  The global settlements …

Read More »

Vertex Gains Exclusive Rights for Merck KGaA’s Two DNA Damage Response Inhibitors

Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced that it has entered into an exclusive licensing agreement with Vertex Pharmaceuticals Incorporated, Boston, USA (NASDAQ: VRTX), for two DNA-dependent protein kinase (DNA-PK) inhibitors – …

Read More »